1-hexadecanoyl-sn-glycero-3-phosphocholine : A lysophosphatidylcholine 16:0 in which a hexadecanoyl (palmitoyl) group is attached to the glycero moiety at position 1. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 460602 |
| CHEMBL ID | 3093100 |
| CHEBI ID | 72998 |
| SCHEMBL ID | 11131776 |
| MeSH ID | M0048115 |
| Synonym |
|---|
| 2-[[(2r)-3-hexadecanoyloxy-2-hydroxy-propoxy]-hydroxy-phosphoryl]oxyethyl-trimethyl-ammonium |
| 1-palmitoyl-sn-glycero-3-phosphocholine |
| lpc(16:0/0:0) |
| 1-hexadecanoyl-sn-glycero-3-phosphocholine |
| pc(16:0/0:0) |
| 16:0 lyso-pc |
| lpc(16:0) |
| LMGP01050018 |
| 1-palmitoyl-phosphatidylcholine |
| 3,5,9-trioxa-4-phosphapentacosan-1-aminium, 4,7-dihydroxy-n,n,n-trimethyl-10-oxo-, inner salt, 4-oxide |
| 1-palmitoyl-sn-glycero-3-phosphocholine, synthetic, >=99% |
| 1-16:0-2-lysophosphatidylcholine |
| 1-16:0-lysopc |
| [(2r)-3-hexadecanoyloxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate |
| gpcho(16:0/0:0) |
| gpcho 16:0/0:0 |
| lysopc 16:0/0:0 |
| 1-palmitoyl-2-lysophosphatidylcholine |
| (2r)-2-hydroxy-3-(hexadecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate |
| lpc 16:0/0:0 |
| 1-hexadecanoyl-2-lysophosphatidylcholine |
| gpc(16:0) |
| 1-16:0-lysophosphatidylcholine |
| 1-palmitoyl-gpc (16:0) |
| lypc(16:0/0:0) |
| gpc(16:0/0:0) |
| 1-palmitoyl-gpc |
| CHEBI:72998 , |
| lysopc(16:0/0:0) |
| (2r)-3-(hexadecanoyloxy)-2-hydroxypropyl 2-(trimethylammonio)ethyl phosphate |
| lysophosphatidylcholine(16:0/0:0) |
| 1-hexadecanoyl-sn-glycerol-3-phosphorylcholine |
| 17364-16-8 |
| lysophosphatidylcholine(16:0) |
| lysopc(16:0) |
| lypc(16:0) |
| lpc 16:0 |
| CHEMBL3093100 |
| SCHEMBL11131776 |
| ASWBNKHCZGQVJV-HSZRJFAPSA-N |
| lyso-pc(16:0) |
| HMS3648G17 |
| (2-{[(2r)-3-(hexadecanoyloxy)-2-hydroxypropyl phosphonato]oxy}ethyl)trimethylazanium |
| AS-74920 |
| 1-palmitoyl-sn-glycero-3-phos-phocholine |
| mfcd00036904 |
| 1-palmitoyl-glycero-3-phosphocholine |
| lysopc a c16:0 |
| l--palmitoyl--lysolecithin |
| soy lyso pc, l-alpha-lysophosphatidylcholine (soy), powder |
| 16:0 lyso pc, 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine, powder |
| 16:0 lyso pc, 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine, chloroform |
| DTXSID30914020 |
| 3-(hexadecanoyloxy)-2-hydroxypropyl 2-(trimethylazaniumyl)ethyl phosphate |
| JD6PYE3XUX |
| 3,5,9-trioxa-4-phosphapentacosan-1-aminium, 4,7-dihydroxy-n,n,n-trimethyl-10-oxo-, inner salt, 4-oxide, (7r)- |
| (r)-2-hydroxy-3-(palmitoyloxy)propyl (2-(trimethylammonio)ethyl) phosphate |
| Q27105001 |
| 3,5,9-trioxa-4-phosphapentacosan-1-aminium,4,7-dihydroxy-n,n,n-trimethyl-10-oxo-, inner salt, 4-oxide, (7r)- |
| lyso-pc |
| AKOS037647823 |
| BP-26337 |
| HY-125783 |
| CS-0099321 |
| PD021403 |
| P2694 |
| BP-26338 |
| Role | Description |
|---|---|
| mouse metabolite | Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| lysophosphatidylcholine 16:0 | A lysophosphatidylcholine in which the acyl group has a fully saturated C16 chain and is attached to the glycero moiety at either position 1 or 2. |
| 1-O-acyl-sn-glycero-3-phosphocholine | The ammonium betaine of a 1-O-acyl-sn-glycero-3-phosphocholine arising from deprotonation of the phosphate OH; major species at pH 7.3. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1058350 | Cytotoxicity against mouse betaTC3 cells assessed as cellular membrane damage at 10 uM after 24 hrs by LDH release assay | 2013 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24 | The chemical synthesis and cytotoxicity of new sulfur analogues of 2-methoxy-lysophosphatidylcholine. |
| AID1058353 | Cytotoxicity against mouse betaTC3 cells assessed as cell viability at 10 uM after 48 hrs by MTT assay relative to control | 2013 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24 | The chemical synthesis and cytotoxicity of new sulfur analogues of 2-methoxy-lysophosphatidylcholine. |
| AID1058354 | Cytotoxicity against mouse betaTC3 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay relative to control | 2013 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24 | The chemical synthesis and cytotoxicity of new sulfur analogues of 2-methoxy-lysophosphatidylcholine. |
| AID1058349 | Cytotoxicity against mouse betaTC3 cells assessed as cellular membrane damage at 25 uM after 24 hrs by LDH release assay | 2013 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24 | The chemical synthesis and cytotoxicity of new sulfur analogues of 2-methoxy-lysophosphatidylcholine. |
| AID1058351 | Cytotoxicity against mouse betaTC3 cells assessed as cell viability at 25 uM after 48 hrs by MTT assay relative to control | 2013 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24 | The chemical synthesis and cytotoxicity of new sulfur analogues of 2-methoxy-lysophosphatidylcholine. |
| AID1058352 | Cytotoxicity against mouse betaTC3 cells assessed as cell viability at 25 uM after 24 hrs by MTT assay relative to control | 2013 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24 | The chemical synthesis and cytotoxicity of new sulfur analogues of 2-methoxy-lysophosphatidylcholine. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||